Read the full guides
Jump to: Overview How it works Dosing Reconstitution FAQ All Articles
Last reviewed: April 18, 2026 by The Peptide Catalog Team
An FDA-approved GHRH analog that builds lean muscle and reduces visceral belly fat. Tesamorelin is the only FDA-approved GHRH analog — clinically shown to build lean muscle while reducing visceral belly fat by 15-18%. Uses the full 44 amino acid GHRH sequence with a trans-3-hexenoic acid modification for stability. Produces physiological GH pulses that drive both protein synthesis in skeletal muscle and lipolysis in abdominal fat. Overview
Core Benefits
Key Advantages
These are educational summaries of commonly discussed effects in wellness/regenerative contexts, not guarantees.
Tesamorelin Results Timeline
Progression
Timeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.
Read the full Tesamorelin results timeline →
Evidence at a glance
Two parallel grades per outcome — clinical RCT depth and real-world community adoption. See the Research Overview below for citations and detail.
Outcome Clinical Evidence Community Evidence Visceral fat reduction in HIV lipodystrophy Strong Moderate Triglyceride / dyslipidemia improvement Strong Moderate MASLD / liver fat (non-HIV) Moderate Moderate Cognitive function in aging Preliminary Moderate How It WorksGHRH Analog (Growth Hormone Releasing Hormone)
Sequence → Stability → GH Pattern → Outcomes
1
Target
GHRH Receptor on Pituitary Somatotrophs
Tesamorelin binds the same GHRH receptor as Sermorelin and CJC-1295. However, Tesamorelin uses the full 44 amino acidGHRH sequence rather than just the first 29, providing a more "native-like" signaling profile.
2
Cellular Signal
cAMP → PKA Cascade → Reliable GH Pulse
Same cAMP/PKA signaling cascade as other GHRH analogs. The trans-3-hexenoic acid cap at the N-terminus increases stability in the bloodstream, resulting in a more predictable and reliable stimulation window compared to shorter fragments.
3
Systemic Effect
Consistent GH Pulses → Fat Loss + Muscle Growth
The reliable GH pulse pattern drives both visceral fat mobilization and lean muscle accrual. Clinical trials showed 15-18% visceral fat reduction alongside increased lean body mass — GH simultaneously upregulates lipolysis in visceral adipocytes and protein synthesis in skeletal muscle.
4
What You Notice
Body Recomposition → Lean Muscle + Less Belly Fat
Users notice reduced abdominal circumference and increased muscle firmness, typically visible within 2-3 months. Improved energy, better lipid panels, and stronger workouts follow. Tesamorelin has the strongest clinical evidence of any GHRH analog for measurable body composition changes in both directions.
What Makes This Peptide Different
Tesamorelin is the only GHRH analog with FDA approval(for HIV-associated lipodystrophy). It uses the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This makes it more "native-like" than the 29-AA fragments ( Sermorelin, CJC-1295) while being more stable than unmodified GHRH. Its clinical validation for both visceral fat reduction and lean mass gains sets it apart from all other GHRH peptides.
Sequence → Why It Matters
Tesamorelin is a nearly full-length GHRH analog with one key modification:
1
Full 44-AA sequence (vs 29-AA fragments)
More complete receptor engagement — closer to native GHRH signaling
2
Trans-3-hexenoic acid at N-terminus
Stability cap — protects against enzymatic degradation, extends effective half-life to ~26-38 min
So what? Being a nearly full-length analog with a stability-enhancing cap gives Tesamorelin the most predictable stimulation window among pulsatile GHRH peptides. This reliability is likely why it has the strongest clinical data for measurable body recomposition — both visceral fat reduction and lean muscle gains.
GHRH Peptide Comparison
Peptide Half-Life GH Pattern What's Unique Sermorelin ~10-20 min Short, natural pulse Native GHRH(1-29) — unmodified, shortest duration CJC-1295 (no DAC) ~30 min Broader natural pulse 4 substitutions for stability — reliable signaling Tesamorelin ~26-38 min Reliable, broader pulse Full 44-AA + hexenoic acid — FDA-approved, builds lean mass CJC-1295 (DAC) 6-8 days Sustained elevation Albumin binding — weekly dosing, non-pulsatile
Research overview
Outcome-by-outcome look at what the evidence actually supports for Tesamorelin, including human vs. animal study counts and our editorial take on each.
Visceral fat reduction in HIV lipodystrophy
Clinical:StrongCommunity:Moderate
Falutz 2007 (NEJM, n=412) randomized HIV patients with abdominal fat accumulation to 2 mg daily SC tesamorelin vs placebo for 26 weeks and showed selective visceral adipose tissue (VAT) reduction of approximately 15-18% vs no change in subcutaneous fat. This is the cleanest demonstration of selective visceral lipolysis by any pharmacologic agent and led to FDA approval in 2010 — the only peptide GHRH analog approved for an adult indication.
4 human studies · 4 animal studies Key findings & citations
VAT reduction ~15-18% over 26 weeks in HIV-associated lipohypertrophy. Subcutaneous fat unchanged — selective visceral effect. FDA-approved 2010 for HIV-associated lipodystrophy (the only adult GHRH analog). Effect reverses on discontinuation.
Top citations
Our take
Best-characterized GHRH analog with a real adult indication. The visceral selectivity is unusual and clinically meaningful.
Liver fat / NAFLD
Clinical:ModerateCommunity:Moderate
Stanley 2014 showed tesamorelin reduced liver fat by MRS in HIV patients with abdominal fat accumulation. The 2019 Stanley follow-up trial (Lancet HIV) showed 37% relative reduction in hepatic fat fraction over 12 months in HIV-NAFLD. Translation to non-HIV NAFLD/MASLD is plausible but not yet demonstrated in published RCTs.
2 human studies · 4 animal studies Key findings & citations
Stanley 2014: liver fat reduction in HIV-associated abdominal fat accumulation. Stanley 2019: 37% relative HFF reduction over 12 months in HIV-NAFLD. Mechanism: visceral fat reduction → reduced hepatic FFA flux → reduced steatosis. No published trial in non-HIV MASLD population.
Top citations
Our take
The cleanest liver-fat data of any peptide. Generalization to non-HIV obesity is reasonable but unproven.
Cognitive function in older adults
Clinical:PreliminaryCommunity:Moderate
Baker 2012 (Arch Neurol, n=152) randomized older adults (66 with MCI) to tesamorelin vs placebo for 20 weeks and showed improved executive function and verbal memory, with attenuation of expected cognitive decline in MCI. Single trial, modest effect sizes — promising but not definitive.
1 human study · 2 animal studies Key findings & citations
Baker 2012: improved executive function vs placebo over 20 weeks. Smaller effect on short-term verbal memory. Cognitive decline in MCI was attenuated relative to placebo.
Top citations
Our take
Single-trial signal, attractive enough that it deserves a Phase 3 nobody has run. Don't assume Alzheimer's slowing without confirmatory data.
What Tesamorelin doesn't do
Claims that current evidence does not support. Worth knowing before you set expectations.
General weight loss without visceral fat focus
Tesamorelin selectively reduces visceral fat. It does not significantly reduce subcutaneous fat or total body weight in published trials — the wrong tool for general fat loss.
Sustaining visceral fat reduction after stopping
VAT regrowth on discontinuation is documented in extension trials. Treatment is effectively indefinite for sustained benefit.
Replacement for tirzepatide in metabolic disease
Incretin agents produce 3-5x larger total weight loss with broader metabolic benefit. Tesamorelin's niche is selective visceral and liver fat, not glycemic control or general obesity.
Use in active malignancy
Tesamorelin elevates IGF-1, and IGF-1 has growth-signal activity in many cancer types. The label specifically contraindicates active or recent malignancy.
Top Tesamorelin Vendors Dosing ProtocolBody Recomposition / Muscle + Fat Loss
Educational reference only. Individual responses vary. Consult healthcare provider before use.
Vial Size
10 mg
Reconstitution
2 ml BAC water
Dose
1 mg (20 units on 1ml syringe)
Timing
AM and/or PM on empty stomach
Frequency
5 days on, 2 days off
Duration
8 weeks on, 8 weeks off
Protocol Notes
Best taken on empty stomach (2+ hr fast). Particularly effective for reducing visceral (belly) fat. FDA-approved dose is 2 mg daily for lipodystrophy.
Why This Dosing Protocol
Why empty stomach? Insulin blunts GH release. Tesamorelin should be taken on an empty stomach (2+ hour fast) to maximize the GH pulse.
Why 5 days on / 2 days off? A common community schedule, generally framed around cost and IGF-1 normalization. The FDA-approved protocol is continuous daily dosing, which trials ran for 52 weeks without tachyphylaxis (see whether GH peptides desensitize).
Why this works for visceral fat: Consistent GH pulses preferentially mobilize visceral adipose tissue. The reliable half-life means each dose hits the same signaling window, creating cumulative fat mobilization over weeks to months.
Full Dosing GuideReconstitution CalculatorCycle Cost Calculator Popular Tesamorelin Stacks
Pre-made bundles ranked by value. Cost per mg is based on the Tesamorelin portion of each stack.
Reconstitution Calculator
Dilution math and unit conversions. Prefilled using a common vial size for this peptide.
Open calculator
Storage & Handling
Storage at a glance
Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.
Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°CView Complete Storage Guide
Handling specifics
Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.
Powder storage (very stable)
Freezer (-20°C): 1+ year Refrigerator (2-8°C): 1-3 months Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
MUST refrigerate at 2-8°C 4-week maximum shelf life NEVER freeze after reconstitution Use bacteriostatic water for multi-dose Molecular Structure
Tesamorelin sequence
Click any residue to see its properties.
HydrophobicPolarAcidic (−)Basic (+)Special
Sequence-derived properties
Length
29 residues
Molecular weight
3358.9 Da
backbone only
Avg hydrophobicity
-0.22
Kyte–Doolittle scale
Residue classes
Hydrophobic: 12 (41%)Polar: 9 (31%)Acidic (−): 2 (7%)Basic (+): 5 (17%)Special: 1 (3%)
Net charge distribution
Positive5 (17%)
Neutral22 (76%)
Negative2 (7%)
Amino acid frequency
L×4A×3R×3S×3D×2I×2K×2Q×2Y×2F×1
Modifications
N-terminal trans-3-hexenoyl group for enzymatic protection
Sequence and properties provided for educational reference. Not for clinical dosing decisions.
Length: 44 amino acids
(Full-length GHRH with N-terminal modification.)
Half-life: ~26–38 minutes
(Longer than sermorelin due to the hexenoic acid modification.)
FDA Status: FDA Approved
(Approved in 2010 for reducing excess abdominal fat.)
Primary Use: Body recomposition
(Reduces visceral fat while increasing lean muscle mass via sustained GH elevation.)
Modified sequence
(trans-3-hexenoic acid)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
The trans-3-hexenoic acid modification at the N-terminus improves stability and bioavailability. FDA-approved for reducing excess abdominal fat.
Key takeaway: Tesamorelin is the only GHRH analog with FDA approval. Its sustained GH elevation both reduces visceral (abdominal) fat and promotes lean muscle growth — clinical trials showed increased lean body mass alongside 15–18% visceral fat reduction. Unlike shorter fragments like Sermorelin (29 AA), Tesamorelin uses the full 44 amino acid GHRH sequence with a stabilizing modification, making it a potent tool for full body recomposition.
FAQ What makes Tesamorelin different from other GHRH peptides?
Tesamorelin is the only GHRH analog that is FDA-approved for a specific therapeutic use (reducing excess abdominal fat). It uses the full 44 amino acid GHRH sequence with a trans-3-hexenoic acid modification, giving it a longer half-life (~26-38 minutes) than sermorelin and making it particularly effective for reducing visceral (abdominal) fat. What are the most common side effects?
In clinical trials, the most common side effects included injection site reactions (redness, itching, swelling), joint pain (arthralgia), and peripheral edema (fluid retention in extremities). Some patients also reported muscle pain and paresthesia (tingling sensations). These effects are generally mild and often decrease with continued use. How effective is Tesamorelin for fat loss?
In FDA clinical trials, Tesamorelin reduced trunk fat by approximately 15-18% over 26 weeks. It specifically targets visceral adipose tissue (VAT) rather than subcutaneous fat, making it particularly effective for reducing dangerous abdominal fat associated with metabolic syndrome and cardiovascular risk. Does Tesamorelin build muscle?
Yes. Tesamorelin stimulates sustained growth hormone release, which drives protein synthesis and lean muscle accrual. Clinical trials showed significant increases in lean body mass alongside visceral fat reduction — making it one of the few peptides clinically demonstrated to shift body composition in both directions simultaneously. The GH elevation also supports faster workout recovery and connective tissue repair, further supporting muscle-building goals. Is Tesamorelin FDA-approved?
Yes. Tesamorelin was FDA-approved in November 2010 specifically for the reduction of excess abdominal fat. This makes it unique among GHRH peptides as it has undergone rigorous clinical trials and regulatory review for this specific indication. What is the typical Tesamorelin dosage?
A common research dosage is 1 mg injected subcutaneously once daily (20 units on 1ml syringe). Best taken AM and/or PM on an empty stomach (2+ hour fast). Protocol: 5 days on, 2 days off, 8 weeks on, 8 weeks off. The FDA-approved dose for lipodystrophy is 2 mg daily. Why does Tesamorelin target visceral fat specifically?
Growth hormone preferentially mobilizes visceral fat (deep abdominal fat around organs) over subcutaneous fat (fat under the skin). Tesamorelin's ability to increase GH levels results in selective reduction of this metabolically dangerous fat. Visceral fat is linked to insulin resistance, cardiovascular disease, and metabolic syndrome. Can Tesamorelin be combined with other peptides?
Yes, some combine Tesamorelin with GHRPs like Ipamorelin for enhanced GH release. Others add AOD-9604 for additional fat loss effects. Since Tesamorelin is FDA-approved, it has more established safety data than most peptides, making it a foundation some build upon. How does Tesamorelin compare to Sermorelin and CJC-1295?
Tesamorelin uses the full 44-amino acid GHRH sequence (vs 29 for Sermorelin), has a longer half-life due to its modification, and is FDA-approved. It's specifically proven for visceral fat reduction. Sermorelin and CJC-1295 are more commonly used for general GH benefits. Tesamorelin is typically more expensive but has stronger clinical validation. How long does reconstituted peptide last?
Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide. Is this peptide legal to purchase?
Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use. New to peptides?
Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.
Scientific Sources
Tesamorelin Research Articles
Compare Tesamorelin to alternatives
Side-by-side mechanism, dose, half-life, and vendor pricing.
Open compare →
Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.